Jacobs Levy Equity Management
BBNX

Jacobs Levy Equity Management’s Beta Bionics BBNX Stock Holding History

Jacobs Levy Equity Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
114,719
+77,345
+207% +$1.14M ﹤0.01% 684
2025
Q4 		$1.14M Sell
37,374
-1,617
-4% -$43.2K ﹤0.01% 661
2025
Q3 		$775K Buy
+38,991
New +$685K ﹤0.01% 763

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jacobs Levy Equity Management's BBNX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Beta Bionics (BBNX) stake by 207% in Q1 2026, buying an estimated $1.14M and bringing the position to 114,719 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #684.

Jacobs Levy Equity Management first reported a position in BBNX in Q3 2025 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Jacobs Levy Equity Management held 114,719 shares of Beta Bionics worth $1.15M as of Q1 2026.
  • Jacobs Levy Equity Management bought 77,345 Beta Bionics shares in Q1 2026, an estimated $1.14M.
  • Beta Bionics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #684 holding.
  • Jacobs Levy Equity Management first reported a position in Beta Bionics in Q3 2025 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.